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Abstract
Background: Estrogens are associated with the loss of skeletal muscle strength in women with age. Ovarian hormone
removal by ovariectomy in mice leads to a loss of muscle strength, which is reversed with 17b-estradiol replacement. Aging
is also associated with an increase in antioxidant stress, and estrogens can improve antioxidant status via their interaction
with estrogen receptors (ER) to regulate antioxidant gene expression. The purpose of this study was to determine if ER and
antioxidant gene expression in skeletal muscle are responsive to changes in circulating estradiol, and if ERs regulate
antioxidant gene expression in this tissue.
Methodology/Principal Findings: Adult C57BL/6 mice underwent ovariectomies or sham surgeries to remove circulating
estrogens. These mice were implanted with placebo or 17b-estradiol pellets acutely or chronically. A separate experiment
examined mice that received weekly injections of Faslodex to chronically block ERs. Skeletal muscles were analyzed for
expression of ER genes and proteins and antioxidant genes. ERa was the most abundant, followed by Gper and ERb in both
soleus and EDL muscles. The loss of estrogens through ovariectomy induced ERa gene and protein expression in the soleus,
EDL, and TA muscles at both the acute and chronic time points. Gpx3 mRNA was also induced both acutely and chronically
in all 3 muscles in mice receiving 17b-estradiol. When ERs were blocked using Faslodex, Gpx3 mRNA was downregulated in
the soleus muscle, but not the EDL and TA muscles.
Conclusions/Significance: These data suggest that Gpx3 and ERa gene expression are sensitive to circulating estrogens in
skeletal muscle. ERs may regulate Gpx3 gene expression in the soleus muscle, but skeletal muscle regulation of Gpx3 via ERs
is dependent upon muscle type. Further work is needed to determine the indirect effects of estrogen and ERa on Gpx3
expression in skeletal muscle, and their importance in the aging process.
Citation: Baltgalvis KA, Greising SM, Warren GL, Lowe DA (2010) Estrogen Regulates Estrogen Receptors and Antioxidant Gene Expression in Mouse Skeletal
Muscle. PLoS ONE 5(4): e10164. doi:10.1371/journal.pone.0010164
Editor: Maurizio C. Capogrossi, Istituto Dermopatico dell’Immacolata, Italy
Received November 11, 2009; Accepted March 22, 2010; Published April 13, 2010
Copyright:  2010 Baltgalvis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by a grant awarded to Dawn A. Lowe from the NIH (R01AG031743). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: baltg001@umn.edu
Introduction
There has been debate as to whether or not estrogen affects the
force-generating capacity of skeletal muscle. A recent meta-analysis
was conducted by our lab examining 23 studies in which
postmenopausal women who were and were not taking estrogen
hormone replacement were subjected to tests of muscle strength [1].
Our findings demonstrated a significant effect of approximately 5%
greater strength in women who were taking estrogen replacement
therapy. These findings are corroborated by a recent study that
examined muscle strength in twins, in which one twin took estrogen
replacement, and the other did not [2]. This paper showed that the
hormone replacement therapy users walked at a maximal speed faster
than non-users, and they had greater muscle power. We have
extended the findings in humans using a mouse ovariectomy model.
We showed that muscle andmyosin functions were reduced,20% in
ovariectomized mice [3], and that those losses in force generation at
both the whole muscle and molecular levels were completely restored
when mice were administered 17b-estradiol [4].
How estradiol confers its beneficial effects to skeletal muscle and
contractile proteins is not known. Theoretically, it could happen
by non-genomic or genomic mechanisms. The most well-described
mechanism for estradiol action in reproductive tissue is its genomic
effects that are mediated through estrogen receptors (ER). In
skeletal muscle, two isoforms of ERs have been identified, estrogen
receptor a (ERa or Esr1) and estrogen receptor b (ERb or Esr2).
These have been identified in multiple species including mice [5]
and humans [6–9]. In human skeletal muscle, ERa mRNA levels
are not different between males and females [6] and are expressed
180-fold greater than ERb mRNA [7]. More recently, ERa and
ERb protein have been detected in human muscle, with about 2/3
of myonuclei staining positive for the receptors [7,9]. Less work
has been done in mouse skeletal muscle. ERa mRNA was detected
in mouse skeletal muscle, but ERbmRNA levels were undetectable
[5]. In addition to ERa and ERb, a third isoform of the estrogen
receptor, G-protein coupled receptor 30 (Gper or GPR30), has
been recognized in several tissues, but is minimally expressed in
skeletal muscle [10,11] and satellite cells [12].
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Most of the work that has been done to elucidate a role for the
different ERs in muscle has been conducted in cell culture. Both
ERa and ERb have been carefully characterized for their
localization in C2C12 cells [13,14]. Human skeletal muscle cells
treated with estrogen increase steroid receptor coactivator (SRC)
and decrease silencing mediator for retinoid and thyroid hormone
receptors (SMRT) mRNAs, suggesting transcriptional activity of
the ER in response to estradiol [15]. Many potential ER-
dependent mechanisms in myoblasts have been investigated,
including their role in stimulating the PI3K/Akt pathway [16],
Glut-4 expression [15], muscle differentiation via upregulation of
myogenin and myosin heavy chain [17], MyoD activity [18], and
prevention of apoptosis [19,20]. While studying the effects of
estrogen and ERs in culture warrants merit and has yielded
important information, intact skeletal muscle is composed of fused
myotubes, is multi-nucleated, and innervated. A physiological
consequence of estrogen deprivation in this complex environment
is a reduction in the force-generating capacity of muscle in both
women and rodents. Therefore, investigating the role of ER-
dependent mechanisms in vivo is necessary to elucidate the
mechanisms by which myosin is affected, and ultimately to
understand the contractile dysfunction that occurs in estrogen-
deficient, aged women.
A link between estradiol-induced changes in ER expression and
muscle function is likely complicated. While the downstream
targets of the ER are many, estrogen-responsive genes that
regulate oxidative stress are interesting to consider. Ovariecto-
mized mice have lower levels of many antioxidant enzymes in the
heart, including glutathione peroxidase, catalase, and superoxide
dismutase [21,22]. Mitochondria from the liver and brain of
ovariectomized mice also produce more H2O2 [23]. However,
these decrements are ablated when estrogen is replaced. These
studies strongly indicate that estradiol plays an important role in
balancing oxidative stress in non-skeletal muscle tissues. In skeletal
muscle, balancing oxidative stress is crucial for myosin function
[24] and overall muscle contractility, particularly during aging
[25]. Elucidating a role for ERs in skeletal muscle most likely
involves linking the ER with both estrogenic and aging effects,
making antioxidant pathways worth investigating.
In summary, the literature illustrates that ERs exist in skeletal
muscle, but whether or not they display typical steroid receptor
responsiveness to their ligand, i.e., estradiol, has not been studied
in intact skeletal muscle. The primary purpose of this study was to
test the hypothesis that ERa, ERb, and Gper in skeletal muscle are
responsive to changes in circulating estradiol. We also began work
to try to understand how estrogen and/or ERs confer a benefit to
skeletal muscle function. Thus, a secondary purpose of this study
was to test the hypothesis that antioxidant gene expression in
skeletal muscle is responsive to changes in circulating estradiol. In
order to probe for a link between ERs and antioxidant function,
we systemically blocked ERs using the ER antagonist, Faslodex.
We hypothesized that blocking ERs would have a detrimental
effect on antioxidant gene expression, providing a ER-dependent
mechanism for estrogen function in skeletal muscle.
Methods
Mice and estrogen manipulations
Four-month-old female C57BL/6 mice were acquired from
Jackson Laboratories (Bar Harbor, ME). Mice were group housed
and had access to phytoestrogen-free food (Harlan-Teklad;
#2019) and water ad libitum. The room was maintained on a
12:12 light:dark cycle. The ovariectomy procedure [3] and 17b-
estradiol pellet implantation procedure [4] were performed as
previously described. Three experiments were performed: (1)
ovariectomy and acute replacement of 17b-estradiol for 48 hours,
(2) ovariectomy and chronic replacement of 17b-estradiol for 3
weeks, and (3) inhibition of ERs for 1 month with Faslodex.
In the acute study, after 7 days of estrogen withdrawal, mice
received a placebo pellet (OVX + Placebo; n=6) or a 17b-
estradiol pellet (OVX + E2; n=6) containing 0.18 mg of 17b-
estradiol in a matrix that is designed to release the hormone (or
placebo) over a 60-day period (Innovative Research of America,
Sarasota, FL). Sham operations were performed (Sham; n=4) on
an additional group of mice. All mice were returned to individual
cages following the subcutaneous pellet implantation and
remained there for 48 hours. In the chronic study, ovariectomies
were performed and mice were implanted with placebo or 17b-
estradiol pellets (n=6 per group) for a total duration of 3 weeks.
This time point was chosen since we previously reported that
skeletal muscle contractile dysfunction occurs between 3 and 4
weeks following ovariectomy [3,4,26].
In the third study, mice were injected weekly with the ER
antagonist ICI 182,780 (FaslodexH, AstraZeneca) at a dose of
10 mg/kg body mass, or a similar volume of mineral oil (n=5 per
group) for a duration of 1 month. A daily dose of approximately
0.1 to 3 mg/kg BM has previously been shown to reduce uterine
mass in mice and rats [27–29]. Mice were placed in voluntary
activity wheels for 3 days before the start of injections, as well as 2
weeks following treatment, as an indicator of physical activity. The
total amount of voluntary physical activity was averaged over the 3
days at each time point. Food intake and body mass was also
monitored on a weekly basis.
At each study’s end, mice were anesthetized with sodium
pentobarbital (100 mg/kg body mass). Blood was collected by
facial vein bleeds and plasma was stored at 280uC for the acute
study. Uterine masses were recorded for the chronic study and the
Faslodex study to ensure the validity of the ovariectomies and
effective blocking of ERs. The soleus and extensor digitorum
longus (EDL) muscles were dissected and immediately processed
for RNA isolation. Tibialis anterior (TA) muscles were also
dissected, snap frozen in liquid nitrogen, and stored at 280uC. All
animal procedures were approved by the University of Minneso-
ta’s Institutional Animal Care and Use Committee.
Circulating estradiol
An ELISA was used to measure 17b-estradiol in the plasma
according to the manufacturers’ specifications (KA0234, Abnova
Corporation, Taiwan). The sensitivity of the assay was 10 pg/mL.
All samples were run in duplicate. Standards were graphed and fit
using a 4-parameter logistic curve fit. Plasma estradiol levels in
sham-operated mice averaged 20620 pg/ml. Circulating estradiol
levels were below the level of detection (10 pg/ml) in all OVX +
Placebo mice, while OVX + E2 mice had an average of
246668 pg/mL.
RNA isolation and DNase treatment
RNA was isolated using Tri ReagentH (Molecular Research
Center, Inc., Cincinnati, OH) according to manufacturers’
instructions. Briefly, muscles were dissected and immediately
homogenized in 1 ml of Tri ReagentH on ice using a PowerGen
homogenizer using 465 s pulses. Samples were incubated at room
temperature for 5 minutes to allow the dissociation of RNA/
protein complexes. Phase separation was achieved using 100 mL of
bromochloropropane and vigorously shaking samples for 15 s.
Samples were allowed to sit at room temperature for 15 minutes,
followed by centrifugation at 12,000 g for 15 min at 4uC. The
supernatant was transferred to a new tube, followed by
ERs in Skeletal Muscle
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precipitation with 500 mL of isopropanol. Samples were incubated
for 10 min at room temperature and centrifuged at 12,000 g for
8 min at 4uC. The supernatant was discarded, the pellet was
washed in 75% EtOH, and the tubes were centrifuged at 7,500 g
for 5 min at 4uC. The pellet was briefly allowed to air dry and was
resuspended in 100 mL of RNase-free H2O, and heated at 55uC
for 10 minutes to help solubilize the RNA. RNA was purified and
concentrated using the RNeasyHMinEluteH Cleanup Kit (Qiagen,
Valencia, CA) according to the manufacturers’ instructions. The
RNA quantity was determined by reading 1 mL of RNA using a
NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientif-
ic, Wilmington, DE) at wavelengths 260 and 280. All 260/280
ratios were $2.0. One or 2.5 mg of RNA was diluted to a total
volume of 8 mL and was treated with 1 mL of RQ1 RNase-free
DNase (Promega, Madison, WI) and 1 mL of DNase buffer at
37uC in a thermal cycler (Techne, Model TC-312, UK) for
30 min. The reaction was terminated using 1 mL of stop solution
and incubating the samples at 65uC for 15 minutes.
cDNA synthesis and PCR Array
cDNA was made using a RT2 First Strand cDNA kit from
SABiosciences (Frederick, MD). Briefly, 1 mg of DNase-treated
RNA in a volume of 10 mL was added to 4 mL of RT buffer, 1 mL
of Primer and External Control Mix, 2 mL of RT Enzyme Mix,
and 3 mL of RNase-free H20. This 20 mL cocktail was incubated
for 15 minutes at 42uC in a thermal cycler. The reaction was
terminated by incubating the samples at 95uC for 5 minutes. The
tubes were then diluted with 91 mL of sterile ddH2O to have a
final volume of 111 mL of diluted cDNA, and stored at 220uC
until the PCR arrays were run.
Oxidative stress and antioxidant defense PCR arrays (PAMM-
065) from SABiosciences were prepared for OVX + Placebo (n= 6)
and OVX + E2 (n= 6) for both soleus and EDL muscles. One PCR
array was used per sample. Each well on the plate was coated with
primers specific for each gene. The PCR cocktail contained
1275 mL of 2x SA Biosciences RT2 master mix (containing SYBRH
green dye), 102 mL of diluted cDNA, and 1173 sterile ddH2O for a
total volume of 2550 mL; 25 mL of this cocktail was added to each
well on plate. Plates were run on a Stratagene Mx3000P
quantitative PCR system. The parameters on the machine included
1 cycle of 10 minutes at 95uC to activate the HotStart DNA
polymerase. This was followed by a 2-step cycling program
consisting of 40 cycles of a denaturing step of 15 sec at 95uC and
an annealing step of 1 minute at 60uC. SYBRH green fluorescence
was detected during the last 15 s of the annealing step. The cycle
threshold (CT) was calculated automatically. The 2
‘(-DDCT)
method was used for detecting changes in gene expression [30].
The DCT was calculated by subtracting the average CT for all 5
housekeeping genes (Gusb, Hprt1, Hsp90ab1, Gapdh, and Actb)
from the gene of interest. Melting curves were run and no primer
dimers were detected. Any wells having a CT greater than 35 were
considered undetectable. Control wells were also used for genomic
DNA contamination, efficiency for reverse transcription, and a
positive PCR control to ensure consistency between the individual
plates. All of these values were within the range suggested by the
manufacturer.
cDNA synthesis and real-time PCR
One mg of DNase-treated RNA was used to synthesize cDNA
using the High Capacity cDNA Reverse Transcription kit from
Applied Biosystems (Foster City, CA). Briefly, 11 mL of DNase-
treated RNA was added to a 9 mL cocktail containing 2 mL 10x
RT buffer, 0.8 mL 25x DNTPs, 2 mL 10x random primers, 1 mL
RT, 1 mL RNase-inhibitor, and 2.2 mL of RNase-free H2O. The
mixture was incubated in a thermal cycler (Techne TC-312, UK)
for 10 min at 25uC, 120 min at 37uC, 5 s at 85uC, and then held
at 4uC overnight. Samples were diluted 1:10 and 1:100 in sterile
ddH2O and stored at 220uC until real-time PCR analysis.
The TaqmanH Gene Expression Assays for mouse-specific ERa
(Mm00433149_m1), ERb (Mm00599819_m1), Gper
(Mm01194814_g1), Gpx1 (Mm00656767_g1), Gpx3
(Mm00492427_m1), Nox4 (Mm00479246_m1), Txnip
(Mm00452393_m1), MyoD (Mm01203489_g1), and Glut-4
(Mm00436615_m1) were all purchased from Applied Biosystems
(Foster City, CA). Eukaryotic 18S rRNA (4333760F) and b-actin
(4352341E) were used as housekeeping genes. Each PCR reaction
contained 9 mL of diluted cDNA,10 mL of 2x Taqman Master
mix, 1 mL of 20x primer, for a total volume of 20 mL in each
reaction. Samples were run in duplicate on ABI 7500 Fast Real-
Time PCR System. The cycling conditions consisted of an initial
step of 50uC for 2 minutes, followed by an initial denaturing step
of 95uC for 10 minutes. The thermal cycler then followed a 2-step
cycling program of denaturing at 95uC for 15 s and annealing at
60uC for 1 minute for a total of 40 cycles. FAM fluorescence was
measured during last 15 s of the annealing step. The 2‘(-DDCT)
method was used for detecting changes in gene expression [30].
The DCT was calculated by subtracting the average of the 18S
rRNA and b-actin CT values from the gene of interest. It should be
noted that the housekeeping genes did not differ between
treatment groups.
Western blotting
Frozen TA muscle was homogenized in 1 ml of ice-cold RIPA
buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA,
pH 8.0, 0.1% Triton-X, 0.1% SDS, 0.5% sodium deoxycholate,
5 mg/mL protease inhibitors (Sigma; P8340), and 10 mg/ml
phosphatase inhibitors (Sigma; P5726). Homogenates were
centrifuged at 10,000 g at 4uC for 10 min and the supernatants
were stored at 280uC. ERa protein was measured by SDS-PAGE
and Western blotting using an anti-mouse ERa (Clone MC-20, sc-
542, Santa Cruz Biotechnology, Santa Cruz, CA) at a 1:250 in
Odyssey Blocking Buffer overnight at 4uC. Visualization of the
antigen-antibody interactions were detected with the secondary
antibody (Goat Anti-Rabbit IRdyeH 680, LI-COR Biosciences,
Lincoln, NE) at a dilution of 1:500 in Odyssey Blocking Buffer.
The membranes were then scanned and quantified using the
OdysseyH Infrared Imaging System (LI-COR Biosciences).
Data analysis
All gene and protein expression data were analyzed using
student t-tests or one-way ANOVAs. Two-way ANOVAs were
used to determine the effect of ER isoforms within muscle type,
antioxidant gene expression within muscle type using the PCR
array, and changes in body mass and wheel running activity over
time. If a significant main effect or interaction existed, Tukey post-
hoc tests were performed. Significance was set at P,0.05.
Results
ERa, ERb, and Gper gene expression in skeletal muscle
Real-time PCR was used to determine the relative abundance of
ERa, ERb, and Gper gene expression in female soleus and EDL
muscles (Figure 1). In both muscles, ERa was the most abundant,
followed by Gper, and ERb was present in the least amount
(P,0.001; Figure 1). We also directly compared ER gene
expression between the slow-twitch soleus and fast-twitch EDL
muscles (Figure 1). EDL muscles had 58% greater expression of
ERa (P = 0.011) and 8-fold greater expression of ERb (P,0.001)
ERs in Skeletal Muscle
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relative to soleus muscle. However, the soleus muscle had 74%
greater expression of Gper (P = 0.003) compared to the EDL
muscle.
ER gene and protein expression are sensitive to
ovariectomy and acute 17b-estradiol replacement
ERa, ERb, and Gper mRNA levels were measured in the soleus
and EDL muscles from sham-operated, OVX + Placebo, and
OVX + E2 mice. There was a significant effect of estradiol status
on ERa expression in both the soleus (P = 0.002) and EDL muscles
(P,0.001). Ovariectomy resulted in muscle ERa mRNA being
,70% greater compared to that in sham mice (Figure 2A). When
17b-estradiol was administered to ovariectomized mice, ERa
mRNA levels came back down to sham levels in both muscles.
ERb mRNA levels were also altered in the EDL muscle
(P = 0.038), with OVX + E2 mice having lower amounts of ERb
compared to sham mice in the EDL muscle. There were no effects
on Gper expression in skeletal muscle in response to ovariectomy in
either the soleus or EDL muscles (Figure 2C). Collectively, these
data show that only ERa responds to acute changes in circulating
17b-estradiol in skeletal muscle.
To determine if the changes in gene expression were
representative of changes in protein expression, we examined
ERa protein levels. To confirm that we were measuring ERa, we
first qualitatively examined ERa protein levels in uterine tissue
and skeletal muscle tissue, and also performed a dose-response
curve in skeletal muscle. Figure 3A shows the relative large
amount of ERa protein in uterine tissue compared to skeletal
muscle, and also verifies that we are able to measure ERa protein
in skeletal muscle. As shown in Figure 3B, ERa protein levels in
the TA muscle responded in the same manner as did mRNA levels
(P,0.001). Muscle from OVX + Placebo mice had about 2-fold
more ERa protein than did those from OVX + E2 mice. Muscle
from estradiol–replaced mice had similar ERa protein levels
compared to those from sham mice.
Acute 17b-estradiol replacement in ovariectomized mice
induces antioxidant gene expression in skeletal muscle
One of the mechanisms by which estrogens may exert a
beneficial effect on skeletal muscle is through its role as an
antioxidant, or by activating ERs to regulate genes related to
oxidative stress. We used PCR arrays to screen 84 genes related to
the antioxidant defense system to determine if estradiol status was
associated with regulation of these genes in skeletal muscle. We
used a two-way ANOVA to compare the effect of treatment
(placebo vs. 17b-estradiol) and muscle type (soleus vs. EDL) to
determine global changes in skeletal muscle gene expression with
estrogen. Our results show that 5 out of the 84 genes measured
were greater in OVX + E2 mice compared to OVX + Placebo
mice in both soleus and EDL muscles (Table 1; P#0.027). These
genes included Gpx3, Gpx2, Nox4, Txnip, and Gpx1. These data
demonstrate that estrogen status can alter antioxidant gene
expression in skeletal muscle.
Chronic estradiol deprivation alters both ER expression
and antioxidant gene expression
For ERs and antioxidant genes to have an impact on skeletal
muscle function, these effects must be chronic in nature. Our next
study was designed to examined ER and antioxidant gene
expression in skeletal muscle following 3 weeks of ovariectomy
with or without 17b-estradiol replacement. First, ERa, ERb, and
Gper gene expression were measured in the soleus, EDL, and TA
muscles from estrogen-deficient and estrogen-replete mice. As
shown in Figure 4A, ERa expression in OVX + E2 mice was 57%,
75%, and 69% of OVX + Placebo mice in the soleus, EDL, and
TA muscles, respectively, similar to results from the previous acute
study (P#0.038). ERb and Gper expression in skeletal muscle from
this chronic study also mimicked the results from the acute study.
Ovariectomized mice expressed similar amounts of ERb and Gper
in all muscles tested relative to those from mice replaced with 17b-
estradiol. These data show that long-term deprivation of estradiol
alters ERa gene expression in skeletal muscle.
Antioxidant gene expression was also quantified in these mice.
Instead of screening 84 genes using the PCR arrays, individual
PCR reactions were run for 4 out of the 5 genes that we found to
be estradiol-responsive at the 48-hour time point: Gpx3, Gpx1,
Nox4, and Txnip. Gpx2 was not analyzed because it is classically
defined as a gastrointestinal glutathione peroxidase [31]. Only
Gpx3 was responsive in all 3 muscle types following 3 weeks of
ovariectomy and 17b-estradiol replacement (Figure 4B). Gpx3 gene
expression in 17b-estradiol-treated mice was 3.9-, 3.1-, and 3.4-
fold greater, respectively, than that in ovariectomized mice
(P#0.001 for all muscles). There were also modest effects of
Figure 1. ER gene expression in skeletal muscles of 4-mo-old female wild-type mice. Data normalized to ERb in the soleus. Values are
means 6 SEM. *Signifies different from ERa within a muscle type. #Signifies different from ERb within a muscle type. $Signifies different from soleus
muscle.
doi:10.1371/journal.pone.0010164.g001
ERs in Skeletal Muscle
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Gpx1 mRNA (P= 0.035) and Txnip mRNA (P= 0.003) in 17b-
estradiol-treated mice, but this effect only occurred in the EDL
muscle. These data suggest that Gpx3 is positively regulated by
17b-estradiol in skeletal muscle.
Inhibition of ER by Faslodex alters antioxidant gene
expression
Our next study was designed to determine if ERs regulate Gpx3
expression in skeletal muscle. We treated mice for 1 month with
Faslodex, an ER antagonist. There were no differences between oil
and Faslodex-treated mice regarding body mass before or at the
study’s end, but both groups gained weight over the course of the
study at the same rate (Figure 5A; P,0.001). Faslodex did not alter
food intake by the mice (P$0.651). There were no differences in
acute wheel running activity between the 2 groups before the
treatment, but there was a trend after treatment for Faslodex-
treated mice to run 40% less than oil-injected mice (Figure 5B;
P= 0.093). At the end of the study, uterine wet mass was 81% less
in Faslodex-treated mice compared to mineral oil-injected control
mice (Figure 5C; P= 0.015), validating that Faslodex did indeed
block ERs. Although ERa gene expression in the uterus was
unaltered with Faslodex, Gpx1 was downregulated 58% (P= 0.046)
and Txnip mRNA was upregulated 3-fold (Figure 5D; P= 0.016).
Collectively these data validate that the Faslodex treatment was
effective at blocking ERs to decrease uterine mass and alter
antioxidant gene expression in that tissue.
Skeletal muscle mass, ERa, and Gpx3 gene expression were
measured in the soleus, EDL, and TA muscles after Faslodex
Figure 2. ER gene expression in skeletal muscle following ovariectomy and 48 hours of 17b-estradiol replacement. A. ERa gene
expression. B. ERb gene expression. C. Gper gene expression. Data are normalized to sham mice within each muscle. Values are means 6 SEM.
*Signifies different from sham. #Signifies different from OVX + Placebo.
doi:10.1371/journal.pone.0010164.g002
ERs in Skeletal Muscle
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treatment. Muscle mass was unaltered in all 3 muscles (P$0.208;
Figure 5E) as was ERa gene expression (P$0.176; Figure 5F).
There was a 50% decrease in Gpx3 gene expression in the soleus
muscle in response to Faslodex treatment (P = 0.019), but Gpx3
levels remained the same in the EDL and TA muscles (Figure 5G).
Estrogens minimally alter MyoD and Glut-4 mRNA in vivo
Markers of muscle differentiation and hypertrophy, as well as
glucose metabolism were also measured, since estrogen has robust
effects on these markers in cell culture. We found that MyoD
mRNA levels were reduced 45% after 48 hours (P = 0.046) in the
EDL muscle with estrogen, but were unchanged in the soleus
muscle (Figure 6A) compared to ovariectomized mice. Similar
results were found after 3 weeks of replacement where estrogen-
treated mice had MyoD mRNA levels that were ,40% less in the
EDL and TA muscles (P#0.019), but MyoD was not affected in the
soleus (Figure 6B). Glut-4 mRNA levels were not altered in the
soleus, TA, or EDL muscles by ovariectomy at any time point
measured (Figures 6A & 6B).
Discussion
The main findings from this study were that ERa, Gper, and ERb
are all expressed in skeletal muscle, but that only ERa is responsive
to both acute and chronic changes in circulating estradiol. Acute
and chronic changes in circulating estradiol also caused changes in
Gpx3 gene expression. Gpx3 expression appeared to be regulated
by ERs, but this was a muscle-specific response. These results are
Figure 3. ERa protein expression in the TA muscle following ovariectomy and 48 hours of 17b-estradiol replacement. A. Preliminary
work examining ERa expression in uterine tissue and skeletal muscle. Lane 1 = 10 mg of uterine homogenate. Lanes 2-4 = 10, 20, and 40 mg of skeletal
muscle homogenate. B. ERa protein expression in muscle from sham, OVX + Placebo, and OVX + E2 mice. Data are normalized to sham mice. Values
are means 6 SEM. *Signifies different from sham. #Signifies different from OVX + Placebo.
doi:10.1371/journal.pone.0010164.g003
ERs in Skeletal Muscle
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vital first steps in discovering estrogen-mediated mechanisms that
influence skeletal muscle contractility. On the whole, this is an
important topic because the decline in circulating estrogens with
age has been associated with muscle weakness in women. These
findings have been replicated in mice who have undergone
ovariectomies to mimic the low circulating estrogen state and have
been further extended to show that an underlying molecular
explanation for the reduction in force generation involves myosin.
However, it is unknown whether the effects of estrogen on muscle
and myosin functions are via an ER-mediated mechanism. The
current study begins to elucidate this mechanism by examining
skeletal muscle ERs in estrogen deficient and -replete states.
While it is known that ERa and ERb are present in skeletal
muscle, much less is known about Gper. Our first experiment
aimed to determine the relative mRNA abundance of all 3 ERs in
skeletal muscle. Our findings are unique in that this is the first
study to compare all three ER isoforms and their relative
abundance in skeletal muscle. Previous work showed greater
levels of ERa compared to ERb mRNA [5,7], and separate studies
have reported the presence of Gper mRNA in skeletal muscle [32].
Our results complement these previous studies by reinforcing that
ERa mRNA is the most abundant, and we also have added that
Gper is expressed in a moderate amount, in between ERa and ERb.
Our experimental design also allowed us to directly compare the
relative mRNA abundance of these 3 ERs amongst slow-twitch
(soleus) and fast-twitch (EDL) muscles. We found that ERa and
ERb were expressed in higher amounts in the EDL than soleus,
but Gper was found in a greater amount in the soleus compared to
the EDL. These data are somewhat contradictory to previously
published findings. Lemione and coworkers reported that ERa
mRNA was greater in the slow-twitch soleus muscle compared to
the primarily fast-twitch gastrocnemius and EDL muscles in
female rats [33]. ERa protein levels were also reported to be
greater in the soleus compared to the gastrocnemius muscle in
rabbits [34,35]. The discrepancies for these findings could be
based on many variables, including the species studied, age of the
animals, and the methods of detection (e.g., only in our study was
real-time PCR used). In addition, while the soleus is considered a
Table 1. PCR array-determined antioxidant gene expression
following replacement of 17b-estradiol in ovariectomized
mice.
Gene Muscle Fold change P-value
(OVX+E2 vs. OVX+Placebo)
Gpx3 soleus 3.85 ,0.001
EDL 2.19
Gpx2 soleus 1.76 0.003
EDL 1.31
Nox4 soleus 1.71 ,0.001
EDL 1.46
Txnip soleus 1.49 ,0.001
EDL 1.18
Gpx1 soleus 1.43 0.027
EDL 1.46
Values are means in fold difference from OVX + Placebo within each muscle
type. The P-value represents the main effect of estradiol status.
doi:10.1371/journal.pone.0010164.t001
Figure 4. Chronic ovariectomy and 17b-estradiol replacement on ER and antioxidant gene expression in skeletal muscle. A. ERa, ERb,
and Gper gene expression. B. Gpx1, Gpx3, Nox4, and Txnip gene expression. ER and antioxidant gene expression were measured in the soleus, EDL,
and TA muscles after 3 weeks of ovariectomy (OVX + Placebo) or in ovariectomized mice immediately replaced with 17b-estradiol (OVX + E2). Data are
normalized to OVX + Placebo mice within each muscle. Values are means 6 SEM. ND=not detected. *Signifies different from OVX + Placebo.
doi:10.1371/journal.pone.0010164.g004
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slow-twitch muscle in the mouse, the percentage of fibers
exhibiting Type I myosin heavy chain is only about 50%,
compared to approximately 90% of the fibers in soleus muscles
of the rat and rabbit [36]. Nevertheless, our data show that all
three ERs are expressed at the gene level in skeletal muscle, with
ERa being the most abundant, and having more expression in fast-
twitch than slow-twitch muscle in female mice.
Our main objective was to determine how ERs in skeletal
muscle respond to changes in circulating estrogen levels both
acutely and chronically. This is the first report of changes in ER
gene expression resulting from ovariectomy and 17b-estradiol
replacement in skeletal muscle. Our data show that only ERa is
responsive to 17b-estradiol status at both a 48-hour and 3-week
time point. To corroborate our gene expression findings, we also
examined ERa protein expression in the TA muscle, and protein
expression mimicked gene expression. These data are also novel in
that it is the first time ERa protein levels have been shown to be
sensitive to acute changes in circulating estradiol in skeletal
muscle. This places skeletal muscle in the category of an estrogen-
sensitive tissue along with uterus, kidney, and cerebral cortex [37].
This work is also in agreement with others who have found that
ovariectomy induces ERa, but not ERb in white adipose tissue
[38]. It is possible that we did not detect changes in ERb with
ovariectomy because the gene is expressed at such a low
abundance in skeletal muscle. Failing to see a change in Gper
gene expression does not rule it out as a possible important player
in the maintenance of skeletal muscle function. Gper works in other
cell types via signaling through MAPK and PI3K to induce gene
Figure 5. Effects of chronic ER inhibition on uterus and skeletal muscle. A. Body mass. B. Voluntary wheel running activity. C. Uterine wet
mass. D. Uterine gene expression. E. Skeletal muscle mass. F. Skeletal muscle ER gene expression. G. Skeletal muscle Gpx3 expression. ERs were
blocked by administering Faslodex for 1 month to female mice. Data are normalized to oil-injected mice. Values are means6 SEM. *Signifies different
from Oil. $Main effect of time.
doi:10.1371/journal.pone.0010164.g005
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transcription [39]. Therefore, estradiol-induced activation of these
downstream signaling proteins via Gper could play a role in skeletal
muscle function, and more investigation regarding the effects of
Gper on skeletal muscle function are needed.
While it is novel to show changes in ER expression at both the gene
and protein level with circulating estrogens in vivo, our next step was to
begin to elucidate a role for ERs in skeletal muscle function. Since
aging and the loss of estrogens both cause decrements in skeletal
muscle function, and aging and estrogen deficiency are related to
problems with antioxidant capacity, our next step was to see if
antioxidant gene expression is altered in skeletal muscle with
ovariectomy. We screened 84 antioxidant genes in skeletal muscles
from ovariectomized mice 48 hours after treatment with 17b-
estradiol or placebo. Gpx3, Gpx2, Gpx1, Nox4, and Txnip were
increased in both the soleus and EDLmuscles in ovariectomized mice
replaced with 17b-estradiol. However, after 3 weeks of ovariectomy
with or without estradiol treatment, only Gpx3 gene expression was
upregulated in response to the hormone. This held true for all 3
muscles examined, suggesting that it was a global skeletal muscle
response. Gpx3 is classically considered a plasma glutathione
peroxidase, but also has high expression in the kidney, lung, brown
adipose tissue, and white adipose tissue [40]. Females have a higher
concentration of Gpx3 in the serum thanmales [41].Gpx3 can also be
regulated by estrogen in white adipose tissue, with Gpx3mRNA being
nearly 3-fold greater in ovariectomized mice treated with 17b-
estradiol compared to vehicle-treated ovariectomized mice [38]. This
effect is seen as early as 2 hours after treatment, and as long as 3
weeks in response to 17b-estradiol. Our data are in agreement with
Lundholm et al. in that Gpx3 also appears to be very sensitive to 17b-
estradiol in skeletal muscle.
We further investigated whether 17b-estradiol’s effect on Gpx3
expression was regulated by ERs by blocking ER action with
Faslodex. The treatment was successful since uterine masses were
significantly lower in Faslodex-treated mice compared to oil-
injected controls. The thioredoxin antioxidant system has
previously been shown to be highly regulated by estrogen and
Faslodex in the uterus, with 17b-estradiol decreasing and Faslodex
increasing Txnip, a negative regulator of the thioredoxin
antioxidant pathway [42]. In the current study, Faslodex increased
Txnip expression in the uterus, complimenting previously pub-
lished work. However, Gpx3 gene expression was downregulated
with Faslodex only in the soleus muscle. This data is in agreement
with others who have published that Gpx3 is responsive to estradiol
in white adipose tissue, and this is mediated via ERa [38]. Our
data suggests that ERs can regulate Gpx3 gene expression, but this
effect is dependent upon skeletal muscle type, since Faslodex did
not alter Gpx3 expression in the TA or EDL muscle. This result
was somewhat surprising since 17b-estradiol had such a robust
effect on Gpx3 gene expression in all 3 muscles, and ERa gene
expression also responded in a similar fashion in all 3 muscles. One
Figure 6. MyoD and Glut-4 gene expression in ovariectomized mice with and without 17b-estradiol supplementation. A. MyoD and
Glut-4 after 48 hours of estrogen replacement. B. MyoD and Glut-4mRNA expression after 3 weeks of estrogen replacement. Values are means6 SEM.
*Signifies different from OVX + Placebo.
doi:10.1371/journal.pone.0010164.g006
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explanation for the muscle difference could be the oxidative
capacity of the muscle types. The soleus is a highly oxidative
muscle, containing many mitochondria. In cell culture studies of
muscle cells, ERa has been found primarily localized to the
mitochondria [13]. This is in contrast to the TA and EDL which
are relatively more glycolytic, and may have fewer mitochondria.
Since estradiol induced Gpx3 gene expression in the TA and
EDL, but this effect was not blocked by Faslodex, estrogen may
also be working indirectly to induce Gpx3 gene expression in these
fast-type muscles. At this point, we can only speculate what this
indirect effect may be. One of the consequences of ovariectomy is
a reduction in physical activity. We and others have shown that
ovariectomized mice that have access to voluntary activity wheels
run approximately 90% less than ovary-intact mice, but running
activity returns to normal with 17b-estradiol replacement [43].
ERa KO mice also demonstrate lower levels of physical activity
[44]. In the current study, there was a non-significant 40%
reduction in voluntary wheel running activity in mice treated with
Faslodex. We should note that voluntary wheel running behavior
was only monitored acutely so exercise would not be a
confounding variable. Physical inactivity is associated with an
increase in oxidative stress [45]. One might speculate that the
potential small decrease in physical activity induced by Faslodex
may not detrimentally affect Gpx3 expression in the TA and EDL.
In contrast, since ovariectomy causes a drastic reduction in
physical activity, this stimulus may be enough to impact Gpx3
expression in the TA and EDL. Only one study has examined the
response of Gpx3 in the serum following an acute bout of exercise,
and it did not change immediately after exercise [41]. More work
is needed to determine the specific response of Gpx3 to acute bouts
and exercise training in skeletal muscle.
An alternative hypothesis regarding the role of estrogen and the
estrogen receptor in skeletal muscle is the ability of estrogen to
affect muscle differentiation. For example, MyoD and Glut-4 have
been previously shown to be highly sensitive to estrogen in muscle
cells in culture, as both of these markers increase with estrogen at
the mRNA and protein levels [15,17]. Furthermore, following
downhill running, satellite cell proliferation is activated to a greater
extent in ovariectomized rats that receive estrogen, as measured by
MyoD, Pax7, and BrdU-labeled nuclei [46,47]. These papers
suggest that estrogen and ERs are important in promoting satellite
cell differentiation, which might also lead to the growth of muscle,
and theoretically the subsequent strength gains seen in women and
mice supplemented with estrogen. However, our data would
suggest that MyoD and Glut-4 are not involved in estrogen’s
positive effect on skeletal muscle contractility. We did not detect
changes in Glut-4 mRNA levels with estrogen in any muscle or
time point tested. In fact, MyoD levels actually decreased ,50%
with estrogen in the TA and EDL muscles at both time points.
Our data are in line with the work of others who have examined
glucose regulation [16,48] and myogenic gene expression [49] in
ovariectomized rats. Intact soleus muscles incubated with estrogen
did not have enhanced glucose uptake, despite increased
phosphorylation in upstream signaling proteins, such as Akt and
AMPK [16]. Furthermore, basal levels of Glut-4 protein and
glucose uptake are not affected by ovariectomy in rats [48]. Unlike
the work done in cell culture, MyoD gene expression increased
nearly 2-fold in the quadriceps muscle of estrogen-deficient mice
compared to controls [49], nearly mimicking the results of our
study. Since estrogen can regulate myogenic gene expression and
promote differentiation in vitro [15,17] and activate satellite cells
after injurious exercise [46,47], we speculate that the beneficial
effects of estrogen on MyoD and Glut-4 expression may involve
inducing satellite cells to undergo differentiation. This would be
important during a period of muscle injury and recovery, but not
necessarily contribute to the mechanism that underlies muscle
weakness that occurs with aging and menopause. Our speculation
is further substantiated by the fact that muscle fiber cross-sectional
area, total protein content, and contractile protein content does
not change with ovariectomy [3,4,50,51] or in ERa2/2 and
ERb2/2 mice [52].
In summary, this study has many findings that have not been
previously reported. First, we showed the relative abundance of
the three ERs in skeletal muscle are, in decreasing order, ERa,
Gper, and ERb. Second, we demonstrated that only ERa is
responsive to circulating estradiol levels at both acute and chronic
time points. Third, Gpx3 gene expression is highly sensitive to 17b-
estradiol in skeletal muscle. Finally, the regulation of Gpx3 by 17b-
estradiol is possibly mediated via ERa in the soleus muscle, but
also indirectly as consequence of ovariectomy, such as physical
activity. Important future work is needed to determine the
importance of Gpx3 in skeletal muscle, and ultimately how this
affects skeletal muscle function during aging.
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